SE0202462D0 - Novel use - Google Patents

Novel use

Info

Publication number
SE0202462D0
SE0202462D0 SE0202462A SE0202462A SE0202462D0 SE 0202462 D0 SE0202462 D0 SE 0202462D0 SE 0202462 A SE0202462 A SE 0202462A SE 0202462 A SE0202462 A SE 0202462A SE 0202462 D0 SE0202462 D0 SE 0202462D0
Authority
SE
Sweden
Prior art keywords
sup
formula
disclosed
novel use
compounds
Prior art date
Application number
SE0202462A
Other languages
English (en)
Swedish (sv)
Inventor
Karolina Lawitz
Grigorios Nikitidis
Peter Sjoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202462A priority Critical patent/SE0202462D0/xx
Publication of SE0202462D0 publication Critical patent/SE0202462D0/xx
Priority to MXPA05001581A priority patent/MXPA05001581A/es
Priority to DE60315674T priority patent/DE60315674T2/de
Priority to AU2003251272A priority patent/AU2003251272A1/en
Priority to US10/524,204 priority patent/US7410966B2/en
Priority to AT03788216T priority patent/ATE370138T1/de
Priority to BR0313461-0A priority patent/BR0313461A/pt
Priority to CNB03823193XA priority patent/CN100358893C/zh
Priority to ES03788216T priority patent/ES2290538T3/es
Priority to JP2004529004A priority patent/JP2006503010A/ja
Priority to KR1020057002263A priority patent/KR20060005333A/ko
Priority to PCT/SE2003/001279 priority patent/WO2004016611A1/en
Priority to EP03788216A priority patent/EP1539759B1/en
Priority to CA002495511A priority patent/CA2495511A1/en
Priority to NZ538156A priority patent/NZ538156A/en
Priority to IL16641305A priority patent/IL166413A0/xx
Priority to ZA200500887A priority patent/ZA200500887B/xx
Priority to NO20051265A priority patent/NO20051265L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE0202462A 2002-08-14 2002-08-14 Novel use SE0202462D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0202462A SE0202462D0 (sv) 2002-08-14 2002-08-14 Novel use
NZ538156A NZ538156A (en) 2002-08-14 2003-08-13 Use of and some novel imidazopyridines
ES03788216T ES2290538T3 (es) 2002-08-14 2003-08-13 Nuevas imidazopiridinas y su uso.
KR1020057002263A KR20060005333A (ko) 2002-08-14 2003-08-13 특정의 신규한 이미다조피리딘 및 그의 용도
AU2003251272A AU2003251272A1 (en) 2002-08-14 2003-08-13 Use of and some novel imidazopyridines
US10/524,204 US7410966B2 (en) 2002-08-14 2003-08-13 Use of and some novel imidazopyridines
AT03788216T ATE370138T1 (de) 2002-08-14 2003-08-13 Neue imidazopyridine und ihre verwendung
BR0313461-0A BR0313461A (pt) 2002-08-14 2003-08-13 Novas imidazopiridinas e respectivo uso das mesmas
CNB03823193XA CN100358893C (zh) 2002-08-14 2003-08-13 一些新的咪唑并吡啶及其用途
MXPA05001581A MXPA05001581A (es) 2002-08-14 2003-08-13 Algunas imidazopiridinas novedosas y su uso.
JP2004529004A JP2006503010A (ja) 2002-08-14 2003-08-13 数種の新規なイミダゾピリジンおよびその使用
DE60315674T DE60315674T2 (de) 2002-08-14 2003-08-13 Neue imidazopyridine und ihre verwendung
PCT/SE2003/001279 WO2004016611A1 (en) 2002-08-14 2003-08-13 Use of and some novel imidazopyridines
EP03788216A EP1539759B1 (en) 2002-08-14 2003-08-13 Novel imidazopyridines and their use
CA002495511A CA2495511A1 (en) 2002-08-14 2003-08-13 Use of and some novel imidazopyridines
IL16641305A IL166413A0 (en) 2002-08-14 2005-01-20 Use of and some novel imidazopyridines
ZA200500887A ZA200500887B (en) 2002-08-14 2005-01-31 Use of and some novel imidazopyridines.
NO20051265A NO20051265L (no) 2002-08-14 2005-03-11 Anvendelse av og noen nye imidazopyridiner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202462A SE0202462D0 (sv) 2002-08-14 2002-08-14 Novel use

Publications (1)

Publication Number Publication Date
SE0202462D0 true SE0202462D0 (sv) 2002-08-14

Family

ID=20288750

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202462A SE0202462D0 (sv) 2002-08-14 2002-08-14 Novel use

Country Status (18)

Country Link
US (1) US7410966B2 (enExample)
EP (1) EP1539759B1 (enExample)
JP (1) JP2006503010A (enExample)
KR (1) KR20060005333A (enExample)
CN (1) CN100358893C (enExample)
AT (1) ATE370138T1 (enExample)
AU (1) AU2003251272A1 (enExample)
BR (1) BR0313461A (enExample)
CA (1) CA2495511A1 (enExample)
DE (1) DE60315674T2 (enExample)
ES (1) ES2290538T3 (enExample)
IL (1) IL166413A0 (enExample)
MX (1) MXPA05001581A (enExample)
NO (1) NO20051265L (enExample)
NZ (1) NZ538156A (enExample)
SE (1) SE0202462D0 (enExample)
WO (1) WO2004016611A1 (enExample)
ZA (1) ZA200500887B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5162236B2 (ja) 2004-03-25 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ イミダゾール化合物
EP1758895A1 (en) 2004-06-17 2007-03-07 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
BRPI0512239A (pt) 2004-06-17 2008-02-19 Wyeth Corp processos para preparação de antagonistas de receptores de hormÈnios liberadores de gonatropina
US7799778B1 (en) * 2005-01-12 2010-09-21 Alcon, Inc. 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
JP5071374B2 (ja) * 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
EP1912987A1 (en) 2005-08-01 2008-04-23 F. Hoffmann-Roche AG Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
BRPI0503681A (pt) * 2005-08-19 2007-04-10 Fundacao Oswaldo Cruz compostos azóis usados como agentes tuberculostáticos e leishmanicidas, composições farmacêuticas contendo os mesmos, uso das respectivas composições farmacêuticas no tratamento ou inibição de doenças, bem como método de tratamento ou inibição de doenças
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
AR057525A1 (es) * 2005-10-03 2007-12-05 Astrazeneca Ab Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
EP1954287B2 (en) † 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
EP1963315B1 (en) * 2005-12-22 2014-10-08 Cancer Research Technology Limited Enzyme inhibitors
JP2009523845A (ja) * 2006-01-23 2009-06-25 クリスタルゲノミクス インコーポレーテッド たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物
ITMI20061581A1 (it) * 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
HRP20110709T1 (hr) * 2007-02-13 2011-11-30 Ab Science Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza
JP2010523490A (ja) * 2007-03-30 2010-07-15 アストラゼネカ・アクチエボラーグ 新規イミダゾ［４，５−ｂ］ピリジン−７−カルボキサミド７０４
WO2008121064A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
WO2009001021A1 (en) * 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
EP2621915B1 (en) * 2010-09-28 2016-04-20 Daewoong Pharmaceutical Co., Ltd Novel method of preparing benzoimidazole derivatives
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103724331A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
CA3103411A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
EP3253754B1 (en) * 2015-02-02 2021-03-31 Kancera AB 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
CA2996177A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
US11008318B2 (en) 2016-07-11 2021-05-18 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
CA3042049A1 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
MX2022010059A (es) 2020-02-18 2022-08-25 Bayer Ag Nuevos compuestos de heteroaril-triazol como pesticidas.
CN113582988B (zh) * 2020-04-30 2025-09-09 正大天晴药业集团股份有限公司 吡啶并环类化合物及其医药用途
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985891A (en) * 1973-02-03 1976-10-12 Boehringer Ingelheim Gmbh 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof
DE3037464A1 (de) * 1980-10-03 1982-05-19 Dr. Karl Thomae Gmbh, 7950 Biberach 6-hydroxy-2-phenyl-imidazo 4,5-b zu pyridine, ihre herstellung und diese sie enthaltende arzneimittel
US5296591A (en) * 1990-12-31 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Trifluoromethylketone derivatives, processes for preparation thereof and use thereof
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
JP2004520299A (ja) * 2000-12-12 2004-07-08 ニューロジェン・コーポレーション スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類

Also Published As

Publication number Publication date
US7410966B2 (en) 2008-08-12
ATE370138T1 (de) 2007-09-15
ZA200500887B (en) 2006-02-22
BR0313461A (pt) 2005-07-05
NO20051265L (no) 2005-05-12
IL166413A0 (en) 2006-01-15
NZ538156A (en) 2006-09-29
WO2004016611A1 (en) 2004-02-26
CN100358893C (zh) 2008-01-02
JP2006503010A (ja) 2006-01-26
EP1539759A1 (en) 2005-06-15
KR20060005333A (ko) 2006-01-17
DE60315674D1 (de) 2007-09-27
CA2495511A1 (en) 2004-02-26
MXPA05001581A (es) 2005-04-25
US20050261333A1 (en) 2005-11-24
AU2003251272A1 (en) 2004-03-03
DE60315674T2 (de) 2008-06-19
CN1684964A (zh) 2005-10-19
EP1539759B1 (en) 2007-08-15
ES2290538T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
IL166413A0 (en) Use of and some novel imidazopyridines
SE0202429D0 (sv) Novel Compounds
IL150635A0 (en) Novel use of phenylheteroalkylamine derivatives
GB0112348D0 (en) Compounds
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MXPA04010055A (es) Derivados de tioxantina como inhibidores de mieloperoxidasa.
SE0202463D0 (sv) Novel compounds
SE0104334D0 (sv) Therapeutic agents
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
SE0301232D0 (sv) Novel use
MY133527A (en) Isoquinoline derivatives
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
SE0201837D0 (sv) Chemical compounds
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
IL150640A0 (en) Novel use of phenylheteroalkylamine derivatives
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
SE0201193D0 (sv) Novel use